Author

A. Luna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:drug response / drug discovery· 3 Organism:human· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Korkut· 2 shared B. Bozorgui· 2 shared C. Sander· 2 shared G. Yan· 2 shared X. Li· 2 shared A. Thomas· 1 shared B. Teicher· 1 shared C. Tlemsani· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Korkut

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Precision combination therapies based on recurrent oncogenic co-alterations

X. Li, E. Dowling, G. Yan, B. Bozorgui, P. Imanirad, J. H. Elnaggar, A. Luna, C. Sander, A. Korkut

The paper develops REFLECT, a method that maps recurrent co-alteration signatures to drug combinations using multi-omic data, validating its effectiveness across 201 cohorts and 10,392 patients.

bioRxiv · Jun 3, 2020Cancer Biology

BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer

G. Yan, H. Wang, A. Luna, B. Bozorgui, X. Li, Z. Dereli, X. Chen, Y. Lu, O. Babur, C. Sander, G. Mills, A. Korkut

This study shows BET inhibition in breast cancer triggers an anti-apoptotic response via MCL1 upregulation, and co-targeting BET and MCL1 is synergistic and effective in basal-like breast cancers.

bioRxiv · Mar 21, 2020Cancer Biology

SCLC_CellMiner: Integrated Genomics and Therapeutics Predictors of Small Cell Lung Cancer Cell Lines based on their genomic signatures

C. Tlemsani, L. Pongor, L. Girard, N. Roper, F. Elloumi, S. Varma, A. Luna, V. N. Rajapakse, R. Sebastian, K. W. Kohn, J. Krushkal, M. Aladjem, B. Teicher, P. S. Meltzer, W. C. Reinhold, , Y. Pommier

SCLC_CellMiner provides an integrated resource of 118 SCLC cell lines with omics data and drug sensitivity, identifying molecular subtypes and therapeutic targets.

bioRxiv · Mar 9, 2020 · PreprintCancer Biology